Mykyta Kachanov, Alexander E Volk, Fabian Falkenbach, Anna Möllring, Jan Hauke, Katrin Rading, Peter Frommolt, Kerstin Becker, Markus Graefen, Rita K Schmutzler, Tobias Maurer, Eric Hahnen, Lars Budäus
{"title":"不同国家综合癌症网络前列腺癌临床实践指南对局限性和局部复发前列腺癌生殖系基因检测的评价。","authors":"Mykyta Kachanov, Alexander E Volk, Fabian Falkenbach, Anna Möllring, Jan Hauke, Katrin Rading, Peter Frommolt, Kerstin Becker, Markus Graefen, Rita K Schmutzler, Tobias Maurer, Eric Hahnen, Lars Budäus","doi":"10.1016/j.euf.2025.05.021","DOIUrl":null,"url":null,"abstract":"<p><strong>Background and objective: </strong>Germline genetic testing (GGT) is useful for identifying prostate cancer (PCa). This study aims to evaluate the GGT criteria according to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines on oncology (NCCN guidelines) for PCa, version 1.2022, for identifying PCa patients to whom GGT at a nonmetastatic stage should be offered.</p><p><strong>Methods: </strong>Consecutive patients referred to our center were assessed using the GGT criteria from the NCCN guidelines version 1.2022. All patients received GGT for the PCa-associated genes ATM, BRCA1, BRCA2, CHEK2, TP53, PALB2, MLH1, MSH2, MSH6, PMS2, and HOXB13. Detection rates of pathogenic or likely pathogenic variants (PGVs) were used to assess the criteria. Additionally, the detection rates of PGVs between different versions of the NCCN guidelines recommended GGT criteria were compared.</p><p><strong>Key findings and limitations: </strong>Of 376 patients, testing was performed prior to radical prostatectomy and salvage lymphadenectomy in 346 (92.0%) and 30 (8.0%) patients, respectively. We detected 47 PGVs in 46 (12.2%) patients. Logistic regression analyses revealed high-risk PCa characteristics as a significant predictor of PGVs (odds ratio 2.19, 95% confidence interval 1.18-4.13, p = 0.01). Applying the GGT criteria outlined in the NCCN guidelines versions 2.2019 and 3.2024, PGVs were detected in 12.5% and 12.6% of the patients, respectively. Compared with the NCCN guideline version 1.2022, both the testing criteria would have missed five patients with PGVs.</p><p><strong>Conclusions and clinical implications: </strong>The GGT criteria outlined in the NCCN guidelines version 1.2022 for nonmetastatic high-risk PCa patients provide a robust framework for identifying patients at a high risk of PGVs. Therefore, GGT should be offered to patients with nonmetastatic PCa in accordance with these GGT criteria.</p>","PeriodicalId":12160,"journal":{"name":"European urology focus","volume":" ","pages":""},"PeriodicalIF":5.6000,"publicationDate":"2025-06-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer.\",\"authors\":\"Mykyta Kachanov, Alexander E Volk, Fabian Falkenbach, Anna Möllring, Jan Hauke, Katrin Rading, Peter Frommolt, Kerstin Becker, Markus Graefen, Rita K Schmutzler, Tobias Maurer, Eric Hahnen, Lars Budäus\",\"doi\":\"10.1016/j.euf.2025.05.021\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background and objective: </strong>Germline genetic testing (GGT) is useful for identifying prostate cancer (PCa). This study aims to evaluate the GGT criteria according to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines on oncology (NCCN guidelines) for PCa, version 1.2022, for identifying PCa patients to whom GGT at a nonmetastatic stage should be offered.</p><p><strong>Methods: </strong>Consecutive patients referred to our center were assessed using the GGT criteria from the NCCN guidelines version 1.2022. All patients received GGT for the PCa-associated genes ATM, BRCA1, BRCA2, CHEK2, TP53, PALB2, MLH1, MSH2, MSH6, PMS2, and HOXB13. Detection rates of pathogenic or likely pathogenic variants (PGVs) were used to assess the criteria. Additionally, the detection rates of PGVs between different versions of the NCCN guidelines recommended GGT criteria were compared.</p><p><strong>Key findings and limitations: </strong>Of 376 patients, testing was performed prior to radical prostatectomy and salvage lymphadenectomy in 346 (92.0%) and 30 (8.0%) patients, respectively. We detected 47 PGVs in 46 (12.2%) patients. Logistic regression analyses revealed high-risk PCa characteristics as a significant predictor of PGVs (odds ratio 2.19, 95% confidence interval 1.18-4.13, p = 0.01). Applying the GGT criteria outlined in the NCCN guidelines versions 2.2019 and 3.2024, PGVs were detected in 12.5% and 12.6% of the patients, respectively. Compared with the NCCN guideline version 1.2022, both the testing criteria would have missed five patients with PGVs.</p><p><strong>Conclusions and clinical implications: </strong>The GGT criteria outlined in the NCCN guidelines version 1.2022 for nonmetastatic high-risk PCa patients provide a robust framework for identifying patients at a high risk of PGVs. Therefore, GGT should be offered to patients with nonmetastatic PCa in accordance with these GGT criteria.</p>\",\"PeriodicalId\":12160,\"journal\":{\"name\":\"European urology focus\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-06-13\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European urology focus\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.euf.2025.05.021\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"UROLOGY & NEPHROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European urology focus","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.euf.2025.05.021","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
Evaluation of Different National Comprehensive Cancer Network Clinical Practice Guidelines in Prostate Cancer for Germline Genetic Testing in Localized and Locally Recurrent Prostate Cancer.
Background and objective: Germline genetic testing (GGT) is useful for identifying prostate cancer (PCa). This study aims to evaluate the GGT criteria according to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines on oncology (NCCN guidelines) for PCa, version 1.2022, for identifying PCa patients to whom GGT at a nonmetastatic stage should be offered.
Methods: Consecutive patients referred to our center were assessed using the GGT criteria from the NCCN guidelines version 1.2022. All patients received GGT for the PCa-associated genes ATM, BRCA1, BRCA2, CHEK2, TP53, PALB2, MLH1, MSH2, MSH6, PMS2, and HOXB13. Detection rates of pathogenic or likely pathogenic variants (PGVs) were used to assess the criteria. Additionally, the detection rates of PGVs between different versions of the NCCN guidelines recommended GGT criteria were compared.
Key findings and limitations: Of 376 patients, testing was performed prior to radical prostatectomy and salvage lymphadenectomy in 346 (92.0%) and 30 (8.0%) patients, respectively. We detected 47 PGVs in 46 (12.2%) patients. Logistic regression analyses revealed high-risk PCa characteristics as a significant predictor of PGVs (odds ratio 2.19, 95% confidence interval 1.18-4.13, p = 0.01). Applying the GGT criteria outlined in the NCCN guidelines versions 2.2019 and 3.2024, PGVs were detected in 12.5% and 12.6% of the patients, respectively. Compared with the NCCN guideline version 1.2022, both the testing criteria would have missed five patients with PGVs.
Conclusions and clinical implications: The GGT criteria outlined in the NCCN guidelines version 1.2022 for nonmetastatic high-risk PCa patients provide a robust framework for identifying patients at a high risk of PGVs. Therefore, GGT should be offered to patients with nonmetastatic PCa in accordance with these GGT criteria.
期刊介绍：
European Urology Focus is a new sister journal to European Urology and an official publication of the European Association of Urology (EAU).
EU Focus will publish original articles, opinion piece editorials and topical reviews on a wide range of urological issues such as oncology, functional urology, reconstructive urology, laparoscopy, robotic surgery, endourology, female urology, andrology, paediatric urology and sexual medicine. The editorial team welcome basic and translational research articles in the field of urological diseases. Authors may be solicited by the Editor directly. All submitted manuscripts will be peer-reviewed by a panel of experts before being considered for publication.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
